natgillin/translations-raw huggingface dataset:
Push the full length of the needle into the skin at a slight angle (45 degrees) with a quick, short motion. 
S hitrim in kratkim gibom celotno dolžino igle zabodite v kožo pod rahlim kotom (45 stopinj).
There are no adequate data with the use of methylnaltrexone bromide in pregnant women. 
Ni zadostnih podatkov o uporabi metilnaltreksonijevega bromida pri nosečnicah.
• Do not use a Relistor pre-filled syringe more than one time, even if there is medicine in the syringe. 
• Napolnjeno injekcijsko brizgo zdravila Relistor uporabite samo enkrat tudi, če je v njej ostalo zdravilo.
Insert the needle straight down into the centre of the vial stopper. 
Zabodite iglo naravnost navzdol v sredino zamaška viale.
Make sure you stop pushing the plunger when you feel resistance. 
Pazite, da boste takrat, ko boste začutili upor, prenehali potiskati bat.
If you push solution back into the vial, slowly pull back the plunger to draw the correct amount of solution back into the syringe. 
Če pri tem potisnete raztopino nazaj v vialo, počasi povlecite bat nazaj, da potegnete pravilno količino raztopine nazaj v brizgo.
N-demethylation of methylnaltrexone bromide to produce naltrexone is not significant, accounting for 0.06 % of the administered dose. 
N-demetilacija metilnaltreksonijevega bromida v naltreksonij ni pomembna, saj predstavlja samo 0,06 % danega odmerka.
No studies were performed in patients with end-stage renal impairment requiring dialysis. 
Pri bolnikih z okvaro ledvic v končnem stadiju, pri katerih bi bila potrebna dializa, niso opravili nikakršnih študij.
If needed, you may cover the injection site with a plaster. 
Če je treba, ga lahko pokrijete z obližem.
In a study comparing single and multiple-dose pharmacokinetic profiles of intravenous methylnaltrexone bromide at a dose of 24 mg between healthy, young (18 to 45 years of age n = 10) and elderly (65 years of age and over n = 10) subjects, the effect of age on exposure to methylnaltrexone bromide was found to be minor. 
V študiji, v kateri so primerjali farmakokinetične profile enkratnih in večkratnih 24-miligramskih intravenskih odmerkov metilnaltreksonijevega bromida pri zdravih mladih (starost 18 do 45 let, n = 10) in starejših (starost 65 let in več, n = 10) preiskovancih, so ugotovili, da je vpliv starosti na izpostavljenost metilnaltreksonijevemu bromidu manj pomemben.
There was no evidence of teratogenicity in rats or rabbits. 
Pri podganah in zajcih ni bilo znakov teratogenosti.
Relistor can be injected without regard to food. 
Zdravilo Relistor lahko injiciramo ne glede na obroke hrane.
• Abdominal pain (stomach ache) 
abdominalna bolečina (bolečina v trebuhu),
Methylnaltrexone bromide does not affect the pharmacokinetics of medicinal products metabolised by cytochrome P450 (CYP) isozymes. 
Metilnaltreksonijev bromid ne vpliva na farmakokinetiko zdravil, ki jih presnavljajo izocimi s citokromom P450 (CYP).
If you experience any of these side effects, which are either severe or will not go away, you should talk to your doctor: 
Če se pri vas pojavi kateri od teh neželenih učinkov, in je resen ali ne mine, se posvetujte s svojim zdravnikom:
Patients had a history of chronic non-cancer pain and were taking opioids with stable doses of at least 50 mg of oral morphine equivalents per day. 
Bolniki so imeli anamnezo kronične bolečine, ki ni posledica raka, in so jemali stabilne odmerke opioidov, ki so ustrezali vsaj 50 mg peroralnega morfina na dan. Bolniki so imeli z opioidi povzročeno konstipacijo
Make sure you have set aside a proper amount of time to complete the injection. 
Poskrbite, da boste imeli na voljo dovolj časa za injiciranje zdravila.
Following intravenous injection of methylnaltrexone bromide, juvenile rats were found to be more sensitive than adult rats to methylnaltrexone-related toxicity. 
Po intravenskem injiciranju metilnaltreksonijevega bromida so ugotovili, da so bili mladiči podgan v primerjavi z odraslimi podganami občutljivejši na toksičnost, povezano z metilnaltreksonom.
Ask your pharmacist how to thow away medicines that you no longer use. 
O načinu odstranjevanja zdravila, ki ga ne uporabljate več, se posvetujte s farmacevtom.
Methylnaltrexone bromide is absorbed rapidly, with peak concentrations (Cmax) achieved at approximately 0.5 hours following subcutaneous administration. 
Metilnaltreksonijev bromid se absorbira hitro, maksimalna koncentracija (Cmax) se doseže približno pol ure po subkutanem odmerku zdravila.
Methylnaltrexone bromide is eliminated primarily as the unchanged active substance. 
Metilnaltreksonijev bromid se odstranjuje iz telesa predvsem kot nespremenjena zdravilna učinkovina.
In a clinical drug interaction study in healthy adult male subjects, a subcutaneous dose of 0.3 mg/kg of methylnaltrexone bromide did not significantly affect the metabolism of dextromethorphan, a CYP2D6 substrate. 
V klinični študiji medsebojnega delovanja zdravil pri zdravih odraslih moških subkutan odmerek 0,3 mg/kg metilnaltreksonijevega bromida ni signifikantno vplival na presnovo dekstrometorfana, ki je substrat CYP2D6.
The renal clearance of methylnaltrexone bromide was reduced following multiple-dose administration of cimetidine (from 31 L/h to 18 L/h). 
Ledvični očistek metilnaltreksonijevega bromida se je po uporabi večkratnih odmerkov cimetidina zmanjšal (z 31 l/uro na 18 l/uro).
For patients with long-term pain (except patients receiving supportive care for advanced illness), fill the syringe to the 0.6 mL mark for 12 mg of Relistor. 
Za bolnike z dolgotrajno bolečino (razen za bolnike, ki prejemajo podporno nego za napredovalo bolezen), injekcijsko brizgo napolnite do oznake 0,6 ml za 12 mg zdravila Relistor.
Packs of more than one vial contain inner cartons consisting of: one vial, one 1 mL injection syringe with retractable injection needle, and two alcohol swabs. 
Pakiranja, ki vsebujejo več kot eno vialo, vsebujejo notranje škatle, ki jih sestavljajo: ena viala, ena 1-mililitrska injekcijska brizga z vskočno injekcijsko iglo in dva alkoholna zloženca.
Clean the injection site with an alcohol swab and let it dry. 
Z alkoholnim zložencem obrišite mesto injiciranja in pustite, da se posuši.
Study 301 compared methylnaltrexone bromide given as a single, double-blind, subcutaneous dose of 0.15 mg/kg, or 0.3 mg/kg versus placebo. 
V študiji 301 so primerjali metilnaltreksonijev bromid, dan kot enkraten, dvojno slep subkutan odmerek 0,15 mg/kg, ali 0,3 mg/kg s placebom.
Severity and worsening symptoms Patients should be advised to promptly report severe, persistent, and/or worsening symptoms. 
Bolnikom je treba svetovati, naj hude ali perzistentne simptome oziroma njihovo poslabšanje, čim prej sporočijo.
Animal studies have shown excretion of methylnaltrexone bromide in breast milk. 
Študije na živalih so pokazale izločanje metilnaltreksonijevega bromida v mleko.
Are you familiar with the technique of self injection or have you discussed this with your doctor (or nurse or pharmacist)? 
Ste seznanjeni s tehniko samoinjiciranja oziroma ste se o tem pogovorili s svojim zdravnikom
Release your thumb from the plunger to allow the protective sleeve to cover the needle. 
Odmaknite palec z bata, da zaščitni etui prekrije iglo.
Subcutaneous injections of Relistor at 150 mg/kg/day decreased fertility in rats. 
Subkutano injiciranje zdravila Relistor v odmerkih 150 mg/kg/dan je pri podganah zmanjšalo plodnost.
As a quaternary amine, the ability of methylnaltrexone bromide to cross the blood-brain barrier is restricted. 
Ker je metilnaltreksonijev bromid kvarterni amin, je njegova sposobnost prehajanja krvno-možganske pregrade omejena.
Carefully pull back the plunger to correct level on syringe (e.g. 0.4 mL if you have been prescribed 8 mg) 
Previdno povlecite bat nazaj na pravilno raven na injekcijski brizgi (npr. 0,4 ml, če vam je bil predpisan odmerek 8 mg)
To prepare the area of skin where Relistor is to be injected, wipe the injection site with an alcohol swab. 
Pripravite predel kože, kamor boste injicirali zdravilo Relistor, tako da mesto injiciranja obrišete z alkoholnim zložencem.
The mean methylnaltrexone bromide exposure at 0.15 mg/kg over a weight range of 38 to 114 kg was 179 (range = 139-240) ng•h/mL. 
Povprečna izpostavljenost metilnaltreksonijevemu bromidu pri odmerku 0,15 mg/kg pri telesni masi med 38 do 114 kg je bila 179 (razpon = 139-240) ng•h/ml.
Durability of response was demonstrated in Study 302, in which the laxation response rate was consistent from dose 1 through dose 7 over the course of the 2-week, double-blind period. 
Trajnost odziva so dokazali v študiji 302, v kateri je bila pogostnost odvajalnega odziva v 2-tedenskem dvojno slepem obdobju nespremenjena od 1. do 7. odmerka.
Following intravenous injection of methylnaltrexone bromide for 13 weeks, similar methylnaltrexone related toxicity was observed in both juvenile and adult dogs. 
Po 13-tedenskem intravenskem injiciranju metilnaltreksonijevega bromida so podobno z metilnaltreksonom povezano toksičnost opazili tako pri mladičih kot pri odraslih psih.
In a study of volunteers with varying degrees of renal impairment receiving a single dose of 0.30 mg/kg methylnaltrexone bromide, renal impairment had a marked effect on the renal excretion of methylnaltrexone bromide. 
V študiji prostovoljcev z različnimi stopnjami ledvičnih okvar, ki so prejeli enkraten odmerek 0,30 mg/kg metilnaltreksonijevega bromida, je ledvična okvara izrazito vplivala na izločanje metilnaltreksonijevega bromida skozi ledvici.
The effect of mild and moderate hepatic impairment on the systemic exposure to methylnaltrexone bromide has been studied in 8 subjects each, with Child-Pugh Class A and B, compared to healthy subjects. 
Vpliv blage in zmerne okvare jeter na sistemsko izpostavljenost metilnaltreksonijevemu bromidu so proučevali na po 8 bolnikih razreda A oziroma B po Child-Pughovi lestvici v primerjavi z zdravimi preiskovanci.
If there are bubbles, gently tap the syringe with your finger until the air bubbles rise to the top of the syringe. 
Če vidite mehurčke, rahlo potrkajte s prstom po brizgi, da se zračni mehurčki dvignejo na vrh brizge.
The capped syringe or syringe and needle should NEVER be reused. 
Pokrite brizge ali brizge s pokrovčkom ne smete NIKOLI uporabiti še enkrat.
Are you receiving opioid therapy (for example morphine or codeine) for your illness? 
Se zdravite z opioidi (na primer z morfijem ali kodeinom)?
In a double-blind, randomised, parallel-group ECG study of single, subcutaneous doses of methylnaltrexone bromide (0.15, 0.30 and 0.50 mg/kg), in 207 healthy volunteers, no signal of QT/QTc prolongation or any evidence of an effect on secondary ECG parameters or waveform morphology was detected as compared to placebo and a positive control (orally administered 400 mg moxifloxacin). 
V dvojno slepi randomizirani študiji EKG s paralelnima skupinama, v kateri so proučevali enkratne subkutane odmerke metilnaltreksonijevega bromida (0,15, 0,30 in 0,50 mg/kg) na 207 zdravih prostovoljcih, niso odkrili nobenega znaka podaljšanja intervala QT/QTc in nobenega dokaza, da bi metilnaltrekson vplival na sekundarne parametre EKG ali morfologijo elektrokardiografskega signala, in to v primerjavi s placebom in pozitivno kontrolo (peroralnim moksifloksacinom v odmerku 400 mg).
The most common adverse reactions in all patients exposed to methylnaltrexone bromide during all phases of placebo-controlled studies were abdominal pain, nausea, diarrhoea and flatulence. 
Najpogostejše neželene reakcije pri vseh bolnikih, ki so bili izpostavljeni metilnaltreksonijevemu bromidu med vsemi fazami s placebom kontroliranih študij, so bile bolečine v trebuhu, navzea, driska in vetrovi.
Relistor contains an active substance called methylnaltrexone bromide which acts by blocking the side effects of opioid pain medicines that affect the bowel. 
Zdravilo Relistor vsebuje učinkovino, imenovano metilnaltreksonijev bromid, ki deluje tako, da zavira neželene učinke opioidnih zdravil na črevesju.
• If you or your doctor know that your bowels were or are obstructed or your bowels are in a state where there is an immediate need for surgical intervention (which has to be diagnosed by your doctor). 
• če vi sami veste ali če vaš zdravnik ve, da imate ali ste imeli zaporo črevesa, ali če je vaše črevo v takšnem stanju, da je potreben takojšen kirurški poseg (diagnozo takega stanja pa mora postaviti vaš zdravnik).
• If you have severe liver or kidney disease. 
• Če imate težko bolezen jeter ali ledvic.
The effects of methylnaltrexone bromide in pregnant women are not known. 
Učinki metilnaltreksonijevega bromida pri nosečnicah niso znani.
If you push the plunger completely, you will hear a ‘click' sound. 
Če boste potisnili bat do konca navzdol, boste zaslišali klik.
There may be local laws about how you should throw away used needles and syringes. 
Morda za odstranjevanje uporabljenih igel in injekcijskih brizg veljajo lokalni predpisi.
INFORMATION IN BRAILLE RELISTOR 8 mg 
PODATKI V BRAILLOVI PISAVI RELISTOR 8 mg
Absolute bioavailability of a 0.30 mg/kg subcutaneous dose versus a 0.30 mg/kg intravenous dose is 82 %. 
Absolutna biološka uporabnost subkutanega odmerka 0,30 mg/kg v primerjavi z intravenskim odmerkom 0,30 mg/kg je 82 %.
Study 3356 compared 4-week treatment regimens of methylnaltrexone bromide 12 mg once daily and methylnaltrexone bromide 12 mg every other day with placebo. 
V študiji 3356 so primerjali 4-tedenski režim zdravljenja z metilnaltreksonijevim bromidom 12 mg enkrat na dan in metilnaltreksonijevim bromidom 12 mg vsak drugi dan s placebom.
The three areas of the body recommended for injection of Relistor are: (1) your upper legs (thighs), (2) your abdomen (stomach), and (3) your upper arm (only if injecting another person). 
Za injiciranje zdravila Relistor so priporočljiva tri mesta: (1) stegno, (2) trebuh in (3) nadlaket (samo če zdravilo injicira nekdo drug).
The double-blind dose was followed by an open-label, 4-week dosing period, where methylnaltrexone bromide could be used as needed, no more frequently than 1 dose in a 24-hour period. 
Dvojno slepemu odmerku je sledilo 4-tedensko obdobje odprtega odmerjanja, med katerim se je metilnaltreksonijev bromid lahko uporabljal po potrebi, a največ 1 odmerek na 24 ur.
Methylnaltrexone bromide is excreted via the milk of lactating rats. 
Metilnaltreksonijev bromid se izloča z mlekom doječih podgan.
How to use Relistor 
Kako uporabljati zdravilo Relistor
The mean steady-state Cmax and AUC for the elderly were 545 ng/mL and 412 ng•h/mL, approximately 8.1 % and 20 %, respectively, greater than those for young subjects. 
Povprečni Cmax in AUC v stanju ravnovesja pri starejših preiskovancih sta bili 545 ng/ml in 412 ng·h/ml, kar je približno za 8,1 %
If you forget a dose, talk to your doctor or pharmacist as soon as possible. 
Če ste pozabili uporabiti odmerek, se čimprej posvetujte z zdravnikom ali farmacevtom.
Results showed no meaningful effect of hepatic impairment on the AUC or Cmax of methylnaltrexone bromide. 
Rezultati niso pokazali pomembnega učinka okvare jeter na AUC ali Cmax metilnaltreksonijevega bromida.
The three areas of the body recommended for injection of Relistor are upper legs, abdomen, and upper arms. 
Trije predeli telesa, ki jih priporočamo za injiciranje zdravila Relistor, so stegno, trebuh in nadlaket.
Elderly population No dose adjustment is recommended based on age (see section 5.2). 
Na podlagi starosti ne priporočajo nikakršnega prilagajanja odmerjanja (glejte poglavje 5.2).
In palliative care patients, Relistor is added to usual laxative treatment (see section 5.1). 
Pri bolnikih, ki prejemajo paliativno nego, se zdravilo Relistor doda običajnemu odvajalnemu zdravljenju (glejte poglavje 5.1).
The effect of severe hepatic impairment on the pharmacokinetics of methylnaltrexone bromide has not been studied. 
Učinka težke okvare jeter na farmakokinetiko metilnaltreksonijevega bromida niso proučevali.
Methylnaltrexone bromide is not recommended in patients with severe hepatic impairment or with end-stage renal impairment requiring dialysis (see section 4.2). 
Metilnaltreksonijev bromid ni priporočljiv za bolnike s težkimi okvarami jeter ali z okvarami ledvic v končnem stadiju, pri katerih je potrebna dializa (glejte poglavje 4.2).
Study 302 compared double-blind, subcutaneous doses of methylnaltrexone bromide given every other day for 2 weeks versus placebo. 
V študiji 302 so primerjali dvojno slepe odmerke metilnaltreksonijevega bromida, ki so ga dajali subkutano 2 tedna vsak drugi dan, s placebom.
If not, do not use the pre-filled syringe and call your nurse, doctor or pharmacist. 
Če ni taka, napolnjene injekcijske brizge ne uporabite in pokličite svojega zdravnika ali farmacevta.
Methylnaltrexone bromide is minimally bound to human plasma proteins (11.0 % to 15.3 %) as determined by equilibrium dialysis. 
Kot so ugotovili z ravnovesno dializo, se metilnaltrekson minimalno veže na beljakovine človeške plazme (11,0 % do 15,3 %).
• If you develop severe or persistent diarrhoea (passing of frequent watery stools), discontinue therapy and contact your doctor immediately. 
• Če se pri vas razvije težka ali trdovratna driska (pogosto odvajanje vodenega blata), prenehajte jemati zdravilo Relistor in se takoj obrnite na svojega zdravnika.
It is unknown whether methylnaltrexone bromide is excreted in human breast milk. 
Ni znano, ali se metilnaltreksonijev bromid izloča v materino mleko.
Step 2: Preparing the injection syringe 
Korak 2: Priprava injekcijske brizge
Only use this medicine if the solution is clear, colourless to pale yellow, and does not contain flakes or particles. 
To zdravilo uporabljajte le, če je raztopina bistra, brezbarvna do svetlo rumena in ne vsebuje kosmičev ali delcev.
The primary endpoint was the proportion of patients with a rescue-free laxation within 4 hours of the double-blind dose of study medicinal product. 
Primarna končna točka je bila delež bolnikov z iztrebljanjem brez rešilnega odvajala v 4 urah po dvojno slepem odmerku preiskovanega zdravila.
It is recommended to move to a different site each time an injection is given. 
Priporočljivo je, da za vsako novo injekcijo izberete drugo mesto injiciranja.
In vitro studies have shown methylnaltrexone bromide to be a mu-opioid receptor antagonist (inhibition constant [Ki] = 28 nM), with 8-fold less potency for kappa opioid receptors (Ki = 230 nM) and much reduced affinity for delta opioid receptors. 
Študije in vitro so pokazale, da je metilnaltreksonijev bromid antagonist mu-opioidnih receptorjev (inhibicijska konstanta [Ki] = 28 nM), z osemkrat manjšo učinkovitostjo za opioidne receptorje kappa
In order to get the air out of the syringe, gently push the plunger down to inject the air into the vial. 
Da boste odstranili zrak iz injekcijske brizge, previdno potisnite bat navzdol, da boste v vialo vbrizgnili zrak.
Relistor is a solution for injection. 
Zdravilo Relistor je raztopina za injiciranje.
The activity of methylnaltrexone bromide has been studied in patients with constipation induced by opioids. 
Aktivnost metilnaltreksonijevega bromida so proučevali pri bolnikih s konstipacijo zaradi jemanja opioidov.
With the needle still in the vial, turn the vial upside-down. 
Ko bo igla še v viali, zasukajte vialo na glavo.
The dose is normally given every 48 hours (every two days) as an injection under the skin. 
Odmerek zdravila se vbrizga pod kožo običajno enkrat na 48 ur (vsak drugi dan).
Opioid-induced constipation in adult patients with chronic pain (except palliative care patients with advanced illness) 
Konstipacija, povzročena z opioidi, pri odraslih bolnikih z napredovalo boleznijo (pri bolnikih, ki prejemajo paliativno nego)
NEVER recap the needle. 
NIKOLI ne smete še enkrat natakniti pokrovčka na iglo.
(≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000) and not known (cannot be estimated from the available data). 
Neželeni učinki so razvrščeni kot: zelo pogosti (≥1/10); pogosti (≥1/100 do <1/10); občasni (≥1/1.000 do <1/100); redki (≥1/10.000 do <1/1.000); zelo redki (<1/10.000)in ni znana (pogostnosti ni mogoče oceniti iz razpoložljivih podatkov).
Important information about some of the ingredients of Relistor This medicine contains less than 1 mmol sodium (23 mg) per dose i.e., essentially “sodium free.” 
Pomembne informacije o nekaterih sestavinah zdravila Relistor To zdravilo vsebuje manj kot 1 mmol (23 mg) natrija na odmerek, kar v bistvu pomeni ‘brez natrija'.
What Relistor looks like and contents of the pack 
Izgled zdravila Relistor in vsebina pakiranja
Slowly push the plunger up to force the air bubbles out of the syringe. 
Počasi pritisnite na bat, da iztisnete zračne mehurčke iz brizge.
Other common side effects that may affect up to 1 in 10 people are: 
Drugi pogosti neželeni učinki, ki lahko prizadenejo največ 1 od 10 bolnikov, so: vrtoglavica (omotičnost),
The efficacy and safety of methylnaltrexone bromide were also demonstrated in open-label treatment administered from Day 2 through Week 4 in Study 301, and in two open-label extension studies (301EXT and 302EXT) in which methylnaltrexone bromide was given as needed for up to 4 months (only 8 patients up to this point). 
dne do konca 4. tedna v študiji 301 in v dveh odprtih podaljšanih raziskavah (301EXT in 302EXT), v katerih so dajali metilnaltreksonijev bromid po potrebi do 4 mesece dolgo (samo 8 bolnikov).
Assemble the supplies you will need for your injection. 
Pripravite si vse, kar boste potrebovali za injiciranje.
Wipe the vial's rubber stopper with an alcohol swab and place it on your flat work surface. 
Obrišite gumijasti zamašek viale z alkoholnim zložencem in položite vialo na ravno delovno površino.
There are no data available from patients with severe hepatic impairment (Child-Pugh Class C), and methylnaltrexone bromide is not recommended in these patients (see section 4.4). 
Podatkov o bolnikih s težkimi okvarami jeter (razred C po Child-Pughovi lestvici) ni na voljo in uporaba metilnaltreksonijevega bromida pri teh bolnikih ni priporočljivo (glejte poglavje 4.4).
Use of methylnaltrexone bromide in patients with known or suspected mechanical gastrointestinal obstruction, patients at increased risk for recurrent obstruction or in patients with acute surgical abdomen is contraindicated due to the potential for gastrointestinal perforation. 
Pri bolnikih, za katere vemo ali sumimo, da imajo mehansko obstrukcijo v prebavilih, bolnikih s povečanim tveganjem za ponavljajočo se obstrukcijo ali pri bolnikih, ki imajo akutni abdomen po kirurškem posegu, je uporaba metilnaltreksonijevega bromida kontraindicirana zaradi možnosti perforacije prebavil.
Single vial 
1 viala
Dispose of the pre-filled syringe as instructed by your doctor, nurse or pharmacist. 
Zavrzite napolnjeno brizgo po navodilih svojega zdravnika, medicinske sestre ali farmacevta.
INFORMATION IN BRAILLE RELISTOR 12 mg/0.6 mL 
PODATKI V BRAILLOVI PISAVI RELISTOR 12 mg/0,6 ml
Remove the syringe and needle from the vial. 
Potegnite iglo z brizgo iz viale.
An integrated analysis of pharmacokinetic data from healthy subjects indicated that methylnaltrexone bromide mg/kg dose-adjusted exposure increased as body weight increased. 
Celovita analiza farmakokinetičnih podatkov, pridobljenih pri zdravih preiskovancih, je pokazala, da se izpostavljenost metilnaltreksonijevemu bromidu, popravljena za odmerek, z naraščanjem telesne mase zvečuje.
If unsure, please contact your doctor, nurse or pharmacist. 
Če ste glede tega negotovi, se posvetujte s svojim zdravnikom, medicinsko sestro ali farmacevtom.
If you get a stomach ache that is either severe or will not go away, stop taking this medicine and call your doctor straight away. 
Če imate hude bolečine v trebuhu, ki ne minejo, prenehajte uporabljati to zdravilo in nemudoma obvestite svojega zdravnika.
Methylnaltrexone bromide-treated patients also had significantly higher rates of laxation within 4 hours after at least 2 of the first 4 doses (52 %) than did placebo-treated patients (9 %); p<0.0001. 
Bolniki, zdravljeni z metilnaltreksonijevim bromidom, so tudi signifikantno pogosteje iztrebljali v 4 urah po vsaj 2 od prvih 4 odmerkov (52 %) kot bolniki, ki so prejemali placebo (9 %); p<0,0001.